Jane Street’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-57,327
| Closed | -$2.75M | – | 13083 |
|
|
2026
Q1 | $2.96M | Buy |
57,327
+20,845
| +57% | +$1.06M | ﹤0.01% | 4369 |
|
|
2025
Q4 | $1.81M | Sell |
36,482
-94,165
| -72% | -$4.58M | ﹤0.01% | 4992 |
|
|
2025
Q3 | $6.24M | Buy |
130,647
+112,008
| +601% | +$4.51M | ﹤0.01% | 3084 |
|
|
2025
Q2 | $588K | Sell |
18,639
-92,541
| -83% | -$2.97M | ﹤0.01% | 6615 |
|
|
2025
Q1 | $3.64M | Buy |
+111,180
| New | +$3.94M | ﹤0.01% | 3408 |
|
|
2024
Q4 | – | Sell |
-52,998
| Closed | -$1.65M | – | 10551 |
|
|
2024
Q3 | $1.65M | Sell |
52,998
-848
| -2% | -$26.5K | ﹤0.01% | 4874 |
|
|
2024
Q2 | $1.44M | Buy |
53,846
+5,940
| +12% | +$172K | ﹤0.01% | 5082 |
|
|
2024
Q1 | $1.63M | Buy |
47,906
+27,991
| +141% | +$833K | ﹤0.01% | 4494 |
|
|
2023
Q4 | $576K | Sell |
19,915
-17,563
| -47% | -$466K | ﹤0.01% | 6523 |
|
|
2023
Q3 | $1.03M | Buy |
37,478
+13,517
| +56% | +$411K | ﹤0.01% | 5140 |
|
|
2023
Q2 | $720K | Buy |
23,961
+7,689
| +47% | +$269K | ﹤0.01% | 5744 |
|
|
2023
Q1 | $590K | Buy |
16,272
+6,492
| +66% | +$250K | ﹤0.01% | 6045 |
|
|
2022
Q4 | $349K | Buy |
9,780
+3,506
| +56% | +$122K | ﹤0.01% | 6763 |
|
|
2022
Q3 | $212K | Sell |
6,274
-11,394
| -64% | -$371K | ﹤0.01% | 8086 |
|
|
2022
Q2 | $511K | Sell |
17,668
-17,225
| -49% | -$493K | ﹤0.01% | 6700 |
|
|
2022
Q1 | $1.13M | Sell |
34,893
-3,836
| -10% | -$118K | ﹤0.01% | 5887 |
|
|
2021
Q4 | $1.13M | Buy |
+38,729
| New | +$1.17M | ﹤0.01% | 5652 |
|
|
2021
Q2 | – | Sell |
-12,902
| Closed | -$396K | – | 10390 |
|
|
2021
Q1 | $338K | Sell |
12,902
-5,130
| -28% | -$143K | ﹤0.01% | 7505 |
|
|
2020
Q4 | $454K | Buy |
+18,032
| New | +$388K | ﹤0.01% | 5889 |
|
|
2020
Q1 | – | Sell |
-45,616
| Closed | -$1.08M | – | 5947 |
|
|
2019
Q4 | $1.08M | Buy |
45,616
+37,792
| +483% | +$918K | ﹤0.01% | 2670 |
|
|
2019
Q3 | $215K | Sell |
7,824
-601
| -7% | -$17.8K | ﹤0.01% | 4571 |
|
|
2019
Q2 | $279K | Sell |
8,425
-11,620
| -58% | -$398K | ﹤0.01% | 4293 |
|
|
2019
Q1 | $703K | Sell |
20,045
-34,546
| -63% | -$1.29M | ﹤0.01% | 3244 |
|
|
2018
Q4 | $1.81M | Buy |
54,591
+44,704
| +452% | +$1.92M | ﹤0.01% | 1855 |
|
|
2018
Q3 | $498K | Buy |
9,887
+1,908
| +24% | +$94.2K | ﹤0.01% | 3622 |
|
|
2018
Q2 | $478K | Buy |
+7,979
| New | +$413K | ﹤0.01% | 3627 |
|
|
2017
Q4 | – | Sell |
-27,134
| Closed | -$1.08M | – | 5156 |
|
|
2017
Q3 | $1.08M | Buy |
27,134
+21,739
| +403% | +$941K | ﹤0.01% | 2208 |
|
|
2017
Q2 | $233K | Buy |
+5,395
| New | +$192K | ﹤0.01% | 3877 |
|
|
2016
Q1 | – | Sell |
-11,083
| Closed | -$149K | – | 4617 |
|
|
2015
Q4 | $149K | Buy |
+11,083
| New | +$171K | ﹤0.01% | 3708 |
|
|
2015
Q2 | – | Sell |
-31,113
| Closed | -$376K | – | 4022 |
|
|
2015
Q1 | $376K | Buy |
+31,113
| New | +$294K | ﹤0.01% | 2317 |
|
|
2014
Q3 | – | Sell |
-99,268
| Closed | -$1.09M | – | 3026 |
|
|
2014
Q2 | $1.09M | Buy |
99,268
+74,537
| +301% | +$664K | 0.01% | 858 |
|
|
2014
Q1 | $221K | Buy |
+24,731
| New | +$228K | ﹤0.01% | 2278 |
|
|
2013
Q4 | – | Sell |
-11,811
| Closed | -$87K | – | 2868 |
|
|
2013
Q3 | $87K | Sell |
11,811
-2,526
| -18% | -$17K | ﹤0.01% | 2560 |
|
|
2013
Q2 | $92K | Buy |
+14,337
| New | +$84.4K | ﹤0.01% | 2453 |
|
Other funds holding SUPN
AC
NAMI
SIMG
Jane Street's SUPN Position: Q2 2026 in Review
Jane Street sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 57,327 shares — an estimated $2.75M sold.
Jane Street first reported a position in SUPN in Q2 2013 and held it in 34 quarters. The position peaked at $6.24M in Q3 2025. 329 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- Jane Street reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jane Street sold 57,327 Supernus Pharmaceuticals shares in Q2 2026, an estimated $2.75M.
- Jane Street first reported a position in Supernus Pharmaceuticals in Q2 2013 and held it in 34 quarters.
- Jane Street's Supernus Pharmaceuticals position peaked at $6.24M in Q3 2025.
- 329 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.